ArticleInternational journal of clinical oncology2026
Impact of periodontitis on the efficacy of neoadjuvant immunochemotherapy in non-small cell lung cancer: a multi-center real-world study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNeoadjuvant immunochemotherapy has revolutionized non-small cell lung cancer(NSCLC) treatment. Periodontitis(PD) is one of the most prevalent oral diseases worldwide; however, its influence on the efficacy of neoadjuvant immunochemotherapy in NSCLC remains unclear. This study aimed to evaluate the association between PD status and severity with treatment outcomes following neoadjuvant immunochemotherapy in NSCLC.
methodsPatients with initial stage IIA-IIIB NSCLC(excluding T4N2 and N3) who underwent surgery after neoadjuvant immunochemotherapy at three institutions between 2019 and 2025 were retrospectively reviewed. Stabilized inverse probability of treatment weighting(IPTW) was employed to balance baseline characteristics. The primary endpoint was major pathological response(MPR) rates.
resultsA total of 51 non-PD and 331 PD cases were included. After IPTW adjustment, PD was associated with lower MPR(33.5% vs. 43.5%, adjusted P = 0.036) and complete pathological response rates, as well as poorer early survival. Increasing PD severity was identified as an independent risk factor for diminished therapeutic efficacy. Specifically, grade II-III PD, but not grade I PD, was associated with poorer pathological response and preliminary survival outcomes. Interaction analyses revealed that such associative patterns were modified by age and body mass index(BMI). Subsequent stratified analyses confirmed that grade II-III PD was correlated with impaired pathological response and early survival in younger(age < 65 years) and non-overweight(BMI ≤ 24.0 kg/m
conclusionPD may be an unfavorable prognostic factor associated with clinical outcomes of neoadjuvant immunochemotherapy in NSCLC. Grade II-III PD may be associated with worse pathological response and early survival, with more pronounced adverse effects in younger and non-overweight patients.
Indexed as
Identifiers
42390727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.